Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Inflammatory Breast Neoplasms × durvalumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 87 Lung Neoplasms 52 Carcinoma, Hepatocellular 43 Breast Neoplasms 33 Small Cell Lung Carcinoma 29 Squamous Cell Carcinoma of Head and Neck 23 Urinary Bladder Neoplasms 21 Colorectal Neoplasms 21 Cholangiocarcinoma 21 Pancreatic Neoplasms 19 Ovarian Neoplasms 17 Triple Negative Breast Neoplasms 16 Biliary Tract Neoplasms 16 Neoplasm Metastasis 13 Head and Neck Neoplasms 12 Neoplasms 11 Carcinoma, Renal Cell 11 Liver Neoplasms 9 Endometrial Neoplasms 9 Carcinoma, Transitional Cell 9 Uterine Cervical Neoplasms 7 Esophageal Neoplasms 7 Carcinoma, Squamous Cell 7 Adenocarcinoma Of Esophagus 7 Recurrence 6 Prostatic Neoplasms 6 Mesothelioma, Malignant 6 Melanoma 6 Gallbladder Neoplasms 6 Fallopian Tube Neoplasms 6

Interventions

Cyclophosphamide 23 Paclitaxel 19 Epirubicin 14 Doxorubicin 13 Carboplatin 13 Trastuzumab 12 Docetaxel 10 Taxes 9 Albumin-Bound Paclitaxel 7 pembrolizumab 5 Radiotherapy 5 Fluorouracil 5 Filgrastim 5 Bevacizumab 5 130-nm albumin-bound paclitaxel 5 pertuzumab 4 Neoadjuvant Therapy 4 Cisplatin 4 eribulin 3 Thiotepa 3 Tamoxifen 3 Panitumumab 3 Melphalan 3 Magnetic Resonance Spectroscopy 3 Flow Cytometry 3 Capecitabine 3 Biopsy 3 sargramostim 2 Specimen Handling 2 Peripheral Blood Stem Cell Transplantation 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05795101 2025-09-19

TRUDI

Dana-Farber Cancer Institute

Phase 2 Recruiting

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡